Ironwood Pharmaceuticals Inc.

10.99+0.0700+0.64%Vol 2.15M1Y Perf 7.85%
Jan 21st, 2022 16:00 DELAYED
BID10.99 ASK11.00
Open10.81 Previous Close10.92
Pre-Market- After-Market10.99
 - -  - -%
Target Price
12.33 
Analyst Rating
Moderate Buy 2.33
Potential %
12.19 
Finscreener Ranking
★★★★     52.20
Insiders Trans % 3/6/12 mo.
-100/-100/-39 
Value Ranking
★★★★★     62.65
Insiders Value % 3/6/12 mo.
-100/-100/67 
Growth Ranking
★★★★★     68.54
Insiders Shares Cnt. % 3/6/12 mo.
-100/-100/70 
Income Ranking
 —    -
Price Range Ratio 52W %
40.26 
Earnings Rating
Sell
Market Cap1.80B 
Earnings Date
16th Feb 2022
Alpha-0.01 Standard Deviation0.11
Beta1.21 

Today's Price Range

10.8111.26

52W Range

8.7814.27

5 Year PE Ratio Range

-20.10100.40

Summary:

Sell

Technical Indicators: Sell
Moving Averages: Strong Sell
Performance
1 Week
-6.23%
1 Month
-5.50%
3 Months
-15.66%
6 Months
-15.40%
1 Year
7.85%
3 Years
-13.60%
5 Years
-25.59%
10 Years
-15.98%

TickerPriceChg.Chg.%
IRWD10.990.07000.64
AAPL162.41-2.1000-1.28
GOOG2 601.84-68.2900-2.56
MSFT296.03-5.5700-1.85
XOM72.17-1.1000-1.50
WFC53.67-1.3300-2.42
JNJ164.87-0.3800-0.23
FB303.17-13.3900-4.23
GE96.30-1.9500-1.98
JPM145.08-2.5800-1.75
Earnings HistoryEstimateReportedSurprise %
Q03 20210.310.336.45
Q02 20210.230.3447.83
Q01 20210.220.249.09
Q04 20200.270.3633.33
Q03 20200.140.2364.29
Q02 20200.080.16100.00
Q01 20200.110.04-63.64
Q04 20190.220.3036.36
Earnings Per EndEstimateRevision %Trend
12/2021 QR0.31-3.13Negative
12/2021 QR0.320.00-
12/2021 FY1.291.57Positive
12/2022 FY1.462.10Positive
Next Report Date16th Feb 2022
Estimated EPS Next Report0.31
Estimates Count3
EPS Growth Next 5 Years %-
Volume Overview
Volume2.15M
Shares Outstanding163.65M
Shares Float87.44M
Trades Count15.83K
Dollar Volume26.63M
Avg. Volume2.34M
Avg. Weekly Volume3.19M
Avg. Monthly Volume2.05M
Avg. Quarterly Volume2.18M

Ironwood Pharmaceuticals Inc. (NASDAQ: IRWD) stock closed at 10.99 per share at the end of the most recent trading day (a 0.64% change compared to the prior day closing price) with a volume of 2.17M shares and market capitalization of 1.80B. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Drug Manufacturers industry, Healthcare sector and employs 232 people. Ironwood Pharmaceuticals Inc. CEO is Mark Mallon.

The one-year performance of Ironwood Pharmaceuticals Inc. stock is 7.85%, while year-to-date (YTD) performance is -5.75%. IRWD stock has a five-year performance of -25.59%. Its 52-week range is between 8.78 and 14.27, which gives IRWD stock a 52-week price range ratio of 40.26%

Ironwood Pharmaceuticals Inc. currently has a PE ratio of 3.60, a price-to-book (PB) ratio of 3.31, a price-to-sale (PS) ratio of 6.47, a price to cashflow ratio of 7.70, a PEG ratio of 2.32, a ROA of 67.75%, a ROC of 72.87% and a ROE of 181.05%. The company’s profit margin is 39.18%, its EBITDA margin is 55.90%, and its revenue ttm is $296.62 Million , which makes it $1.81 revenue per share.

Of the last four earnings reports from Ironwood Pharmaceuticals Inc., there were 4 positive earnings surprise and 0 negative earnings surprise. The company has EPS estimate of $0.31 for the next earnings report. Ironwood Pharmaceuticals Inc.’s next earnings report date is 16th Feb 2022.

The consensus rating of Wall Street analysts for Ironwood Pharmaceuticals Inc. is Moderate Buy (2.33), with a target price of $12.33, which is +12.19% compared to the current price. The earnings rating for Ironwood Pharmaceuticals Inc. stock is Sell (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

Ironwood Pharmaceuticals Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

Ironwood Pharmaceuticals Inc. has a Sell technical analysis rating based on Technical Indicators (ADX : 10.82, ATR14 : 0.44, CCI20 : -177.79, Chaikin Money Flow : -0.31, MACD : -0.14, Money Flow Index : 28.62, ROC : -6.31, RSI : 41.55, STOCH (14,3) : 13.85, STOCH RSI : 0.19, UO : 33.36, Williams %R : -86.15), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of Ironwood Pharmaceuticals Inc. in the last 12-months were: Alexander J. Denner (Buy at a value of $10 094 250), Edward P. Owens (Buy at a value of $110 370), Jason Rickard (Sold 45 389 shares of value $519 142 ), Julie H. McHugh (Sold 10 000 shares of value $110 200 ), Michael Shetzline (Sold 17 930 shares of value $210 413 ), Ronald Silver (Sold 2 029 shares of value $24 573 ), Thomas A. McCourt (Sold 102 403 shares of value $1 180 251 )

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
1 (33.33 %)
1 (33.33 %)
1 (25.00 %)
Moderate Buy
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Hold
2 (66.67 %)
2 (66.67 %)
3 (75.00 %)
Moderate Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Strong Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Summary RatingModerate Buy
2.33
Moderate Buy
2.33
Moderate Buy
2.50

Ironwood Pharmaceuticals Inc.

Ironwood Pharmaceuticals is a specialty and generic drug manufacturing company that operates a human therapeutics segment. The company is focused on advancing innovative product opportunities in areas of large unmet need, including irritable bowel syndrome with constipation, chronic idiopathic constipation, hyperuricemia associated with uncontrolled gout, uncontrolled gastroesophageal reflux disease, and vascular and fibrotic diseases. The company considers collaborative licenses, commercial agreements, and acquisition investment to be potential components of its operational growth strategy for expanding its research, development, manufacturing, and marketing capabilities.

CEO: Mark Mallon

Telephone: +1 617 621-7722

Address: 100 Summer Street, Boston 02110, MA, US

Number of employees: 232

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

50%50%

Bearish Bullish

60%40%

Bearish Bullish

44%56%

Bearish Bullish

50%50%

News

Stocktwits